~~<i id='581C6728FF'><strike id='581C6728FF'><tt id='581C6728FF'><pre id='581C6728FF'></pre></tt></strike></i>~~

Home» explore» knowledge

knowledge

author：focus 2025-10-02 23:35:10 Page View：667

Hiram Secrist (left), who has Duchenne muscular dystrophy, with his mother, Kristen Secrist (center), and his grandmother, Terrie Jordan. Courtesy Secrist family

In mid-July, Kristen Secrist hopped on a call with her 5-year-old son’s doctor, who had urgent news: The first gene therapy had been approved for Duchenne muscular dystrophy. Her son, Hiram, would be a perfect candidate — if, she added, they could get him dosed in time.

The treatment was approved only for 4- and 5-year-olds. Hiram turned 6 in three weeks.

“Oh, crap,” Secrist said to herself.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Scientists successfully use ultrasound imaging to map brain activity
Next article： Virginia high school admissions case could be legal follow

explore

New air purifier tech could be key to improving indoor air quality

AdobeUntiltheearly20thcentury,Americaregularlyexperiencedbrutallydestructiveurbanfires.Conflagration

Startling documents reveal new facets of Sacklers' opioid empire

TheSacklernameadornsbuildingsandwingsofbuildingsatsomeoftheworld'stopuniversitiesandmuseums,likethis

23andMe had bad news about my health. I wish a person had delivered it

ERICBARADAT/AFP/GettyImagesLastsummer,IthoughtitmightbefuntohavemyDNAanalyzed.Twocompanies,23andMean

Biohaven protein

SpencerPlatt/GettyImagesBiohavenPharmaceuticalssaidWednesdaythatanewtypeofexperimentalmedicinereduce